Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 1,002 put options on the company. This is an increase of 1,791% compared to the average volume of 53 put options.

Maravai LifeSciences Stock Up 3.8%

MRVI stock traded up $0.09 during trading hours on Friday, hitting $2.47. The company's stock had a trading volume of 6,240,265 shares, compared to its average volume of 2,289,688. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $629.01 million, a PE ratio of -2.17 and a beta of 0.25. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $10.03. The stock has a 50 day moving average price of $2.15 and a two-hundred day moving average price of $3.26.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. Maravai LifeSciences's revenue for the quarter was down 26.9% compared to the same quarter last year. On average, equities research analysts expect that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Institutional Trading of Maravai LifeSciences

Several large investors have recently modified their holdings of MRVI. Alyeska Investment Group L.P. boosted its holdings in shares of Maravai LifeSciences by 145.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock worth $29,045,000 after buying an additional 3,161,072 shares during the period. Marshall Wace LLP boosted its holdings in shares of Maravai LifeSciences by 17,912.9% during the 4th quarter. Marshall Wace LLP now owns 2,778,497 shares of the company's stock worth $15,143,000 after buying an additional 2,763,072 shares during the period. Philosophy Capital Management LLC bought a new stake in shares of Maravai LifeSciences during the 1st quarter worth $5,731,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Maravai LifeSciences by 29.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock worth $25,420,000 after buying an additional 1,062,485 shares during the period. Finally, 12 West Capital Management LP boosted its holdings in shares of Maravai LifeSciences by 8.0% during the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock worth $27,672,000 after buying an additional 930,000 shares during the period. 50.25% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MRVI. Morgan Stanley lowered their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Tuesday, March 25th. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Bank of America lowered their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. Finally, UBS Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $6.64.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.